Antiphospholipid syndrome as a cause of portal vein thrombosis. Two cases;Thrombose portale revelant un syndrome des antiphospholipides. Deux cas

Gastroenterologie Clinique et Biologique

Volumn 20, Issue 10, 1996, Pages 897-900

  Bouaniche, Marc ^a   Guédon, Claire ^a   Borg, Jeanne Yvonne ^a   Zalar, Alberto ^a   Ducrotté, Philippe ^a   Lerebours, Eric ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

anticardiolipin antibodies; antiphospholipid antibodies; lupus anticoagulant; portal hypertension; portal vein thrombosis

Indexed keywords

LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; ANTICOAGULANT AGENT;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; DIAGNOSTIC TEST; ESOPHAGUS VARICES BLEEDING; HUMAN; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; SCLEROTHERAPY; ADULT; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; MIDDLE AGED; PORTAL VEIN; THROMBOSIS; TIME;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PORTAL VEIN; THROMBOSIS; TIME FACTORS;

EID: 0029909158     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
2. Alarcon-Segovia D, Deleze M, Onia CV, Sanchez-Guerero J, Gomez-Pacheco L, Cabredes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353-65.
3. Ashershon RA, Khamashta MA, Ordi-Ros J, Derksen RHW, Machin SJ, Barquinero J, et al. The « primary » antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68:366-74.
4. Macworth-Young CG, Larizon S, Walport MI. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorders. Ann Rheum Dis 1989;48:362-7.
5. Mannoussakis MN, Tzioufus AH, Silin MP. High prevalence of anticardiolipin and other auto antibodies in a healthy elderly population. Clin Exp Immunol 1987;138:256-62.
6. Lowood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989;16:369-73.
7. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Shur PH, Hennekens CH, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002.
8. Amiral J, Minard F, Chambrette B. Development of standardized immunoassays for identification, characterization and quantitation of antiphospholipid antibodies. Biol Clin Hematol 1991;13:81-8.
9. Harris EN, Phil M. The second international anticardiolipin standardisation workshop. The Kingston Antiphospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990;94: 474-84.
10. Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra hepatic venous obstruction. Q J Med 1979; 48:627-39.
11. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988;94:1063-9.
12. Harris EN, Baguley E, Ashershon RA, Hughes GRV. Clinical and serological features of the « antiphospholipid antibodies syndrome » (abstract). Br J Rheumatol 1987;26 (suppl 2):19.
13. Harris EN. A reassessment of the antiphospholipid syndrome. J Rheumatol 1990;17:733-5.
14. Piette JC, Wechsler B, Blétry O, Godeau P. Quels critères pour le diagnostic du syndrome des antiphospholipides? Rev Med Interne 1993; 14: 799-803.
15. Perez-Vasquez ME, Villa AR, Drenhard C. Influence of disease duration, continued follow-up and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with SLE. J Rheumatol 1993;20:417-21.
16. Gharavi AE, Harris EN, Ashershon RA. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987;46:1-6.
17. De Clerk LS, Mickaelson PP, Jausseus E, Van Maercke YM, Van Mark EA, Stevens WJ. Portal and pulmonary vessel thrombosis associated with systemic lupus erythematous and anticardiolipin antibodies. J Rheumatol 1991;18:1919-21.
18. Ordi J, Vargas V, Valardell M, Basquinero J, Guardia J. Lupus anticoagulant and portal hypertension. Am J Med 1988;84: 566-7.
19. Piette JC, Wechsler B, Blétry O, Godeau P. Exclusion criteria for the primary antiphospholipid syndrome. J Rheumatol 1993;20:1802-4.
20. Piette JC. Prevention of recurrent thrombosis in the antiphospholipid syndrome. Lupus 1994;3:73-4.
21. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
22. Derksen R, De Groot PG, Keter L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long-term anticoagulant treatment. Ann Rheum Dis 1993;52:689-92.
23. Rivier G, Herranz MT, Khamashta MA, Hughes GRV. Thrombosis and antiphospholipid syndrome. A preliminary assessment of three antithrombotic treatments. Lupus 1994;3:91-6.
24. Cappel M, Mikhail N, Gujral N. Gastrointestinal hemorrhage and intestinal ischemia associated with anticardiolipin antibodies. Dis Dig Sci 1994;39:1359-64.
25. Ashershon RA, Thompson RPH, MacLachan N, Baguley E, Hicks P, Hughes GRV. Budd Chiari syndrome, visceral arterial occlusions, recurrent fetal loss and the lupus anticoagulant in the systemic lupus erythematous. J Rheumatol 1989; 16:219-24.